Carcinome épidermoïde de la joue（CEJ） - Guide de tourisme médical et soins en Chine

Buccal squamous cell carcinoma (BSCC) is a malignancy arising from the mucosal epithelium of the cheek. Treatment planning depends on tumour size, depth of invasion (T-stage), nodal involvement (N-stage), patient age, comorbidities, and functional status. Early-stage lesions (T1–T2, N0) may be managed with organ-preserving approaches. Advanced cases (T3–T4 or N+) typically require multimodal strategies. Final decisions rest with the oral and maxillofacial surgery team after biopsy, MRI/CT imaging, and clinical staging.

Option 1: Conservative & Non-Surgical Management Used only for very small, superficial, biopsy-confirmed low-grade lesions in medically frail patients unfit for surgery. Includes topical 5-fluorouracil cream or imiquimod — applied under supervision. Not curative for invasive disease. Estimated cost: USD 180–320 for 6-week course (includes dermatology follow-up at Peking University School of Stomatology, Department of Oral Medicine). Radiation therapy alone (e.g., external beam radiotherapy at Shanghai Ninth People’s Hospital, Department of Oral and Maxillofacial Oncology) starts at USD 4,200 for full course — but rarely used monotherapeutically for buccal SCC.

Option 2: Surgical Intervention Primary treatment for most cases. Options include transoral excision (for T1–T2), composite resection with partial buccal mucosa + underlying fat/muscle (T2–T3), or radical resection with neck dissection (T3–T4/N+). Reconstruction uses local flaps (buccal fat pad, nasolabial) or free tissue transfer (fibula or anterolateral thigh flap). Pre-op workup (PET-CT, dental CT, pathology review) costs USD 1,100–1,900. Surgery + 7-day hospital stay ranges USD 7,800–14,500 depending on reconstruction complexity. Costs reflect Grade 3A public hospitals like West China Hospital (Sichuan University) or Sun Yat-sen University Cancer Center.

Option 3: Complex or Resistant Cases For recurrent, perineural invasion, or margin-positive resections: adjuvant intensity-modulated radiotherapy (IMRT) at Beijing Stomatological Hospital (USD 5,300–7,100) or concurrent chemoradiation (cisplatin-based; adds USD 1,600–2,400). Targeted therapy (cetuximab) or immunotherapy (pembrolizumab) are available off-label but not standard first-line; estimated monthly cost USD 2,900–4,700.

Quick Selection Guide Younger, fit patients with T1–T2 lesions → surgery preferred. Older adults with significant cardiac/respiratory disease → consider radiation-only if lesion is small and well-defined. Budget-constrained patients → transoral excision at lower-tier Grade 3A hospitals (e.g., Zhengzhou University First Affiliated Hospital) may reduce surgical cost by ~25%. Patients with prior head/neck radiation → require IMRT planning expertise — factor in longer scheduling lead time (typically 2–4 weeks). Our platform can help you compare quotes across partner hospitals, arrange pathology second opinions, and coordinate pre-travel medical records review.